Bayer | BAYN - Cash And Equivalent


Bayer reported EUR5.73B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Air Liquide EUR 3.96B 2.05B Dec/2025
Akzo Nobel EUR 2.76B 1.14B Mar/2026
Alcon AG USD 1.58B 80M Mar/2026
Amarin USD 143.56M 12.5M Jun/2026
Arkema EUR 1.73B 458.1M Mar/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BASF EUR 7.8B 4.71B Jun/2026
Bayer EUR 5.73B 943M Mar/2026
Beiersdorf EUR 1.2B 33M Dec/2025
Corteva USD 2.37B 401M Jun/2026
Covestro EUR 648M 44M Dec/2025
Essilor EUR 3.54B 758M Dec/2025
Fresenius EUR 2.06B 752M Mar/2026
Fresenius Medical Care EUR 1.24B 343.37M Mar/2026
Genmab DKK 1.5B 18M Jun/2026
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 513M 189M Jun/2026
Henkel EUR 2.71B 163M Dec/2025
Hikma Pharmaceutical USD 217M 19M Dec/2025
Johnson Matthey GBP 542M 49M Jun/2024
Linde USD 3.96B 1.1B Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.74B 415M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Nutrien USD 921M 144M Jun/2026
Philips EUR 1.79B 803M Jun/2026
PPG Industries USD 1.52B 53M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
SAP EUR 10.04B 1.83B Mar/2026
Solvay EUR 367M 119M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024
Umicore EUR 1.56B 450.17M Dec/2025
Vinci EUR 17.25B 2.18B Dec/2025